Arvinas (ARVN) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MapLight Therapeutics is the larger company by market cap ($508.5 million vs $484.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | MPLT |
|---|---|---|
| Share price | $7.51 | $9.15 |
| Market cap | $484.55M | $508.52M |
| 1-day change | +0.81% | -2.24% |
| YTD return | -36.68% | -47.91% |
| 1-year return | -22.97% | — |
| 5-year return | -91.18% | — |
| P/E ratio (TTM) | 28.88 | — |
| EPS (TTM) | $0.26 | $-6.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $40.43 |
| 52-week low | $6.97 | $8.92 |
| Distance from 52-week high | -48.24% | -77.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +85.49% | +190.05% |
| Average volume | 788.21K | 851.70K |
| Shares outstanding | 64.52M | 52.85M |
| Employees | 246 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
ARVN vs MPLT FAQ
Which is bigger, Arvinas or MapLight Therapeutics?
MapLight Therapeutics (MPLT) is larger, with a market capitalization of $508.52M compared with $484.55M for Arvinas (ARVN).
Are Arvinas and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.